Lundbeck drug Cipralex approved for the treatment of GAD in Europe  

2005.09.23
Danish pharmaceutical company Lundbeck has announced that the European health authorities have approved the company's drug Cipralex for the treatment of generalised anxiety disorder (GAD)

Danish pharmaceutical company Lundbeck has announced that the European health authorities have approved the company's drug Cipralex [escitalopram, marketed as Lexapro in the US – Ed] for the treatment of generalised anxiety disorder (GAD). In Europe, Cipralex is also approved for the treatment of depression, social disorder and panic disorder. The approval was based on seven clinical studies involving more than 1,600 patients from Europe and North America.

Executive vice president of Lundbeck, Ole Chrintz, who is responsible for sales and marketing in Europe, says the approval of Cipralex for the treatment of GAD strengthens the drug's market position. GAD is reportedly a relatively common anxiety problem, affecting some 8% of the population worldwide at some point in their lives. Nearly 20 million people are estimated to be GAD afflicted in the Western world. The news was reported by financial daily newspaper Børsen and on Lundbeck's website.

Lundbeck is an international pharmaceutical company engaged in R&D, production, marketing and sales of drugs for the treatment of psychiatric and neurological disorders. In 2004, the company generated revenues of DKK 9.7 bn (USD 1.5 bn). Lundbeck is headquartered in Copenhagen and employs approx. 5,000 people.

Link > Lundbeck 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×